Trulieve Cannabis (OTCMKTS:TCNNF)‘s stock had its “buy” rating reissued by investment analysts at Needham & Company LLC in a research note issued to investors on Monday, AnalystRatings.com reports. They presently have a $20.00 target price on the stock. Needham & Company LLC’s price objective suggests a potential upside of 52.79% from the stock’s current price.
Separately, Compass Point raised shares of Trulieve Cannabis from a “neutral” rating to a “buy” rating and lifted their price target for the company from $11.00 to $17.00 in a report on Monday, December 2nd.
Shares of OTCMKTS:TCNNF opened at $13.09 on Monday. Trulieve Cannabis has a 1-year low of $6.68 and a 1-year high of $16.23. The firm’s 50 day simple moving average is $11.38 and its two-hundred day simple moving average is $10.22.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge.
Featured Article: Initial Coin Offerings entail a high degree of risk
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.